Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The interval between progression and therapy initiation is the key prognostic parameter in relapsing diffuse large B cell lymphoma: analysis from the Czech Lymphoma Study Group database (NIHIL)

A. Janikova, J. Michalka, Z. Bortlicek, R. Chloupkova, V. Campr, N. Kopalova, P. Klener, K. Benesova, J. Hamouzova, D. Belada, V. Prochazka, R. Pytlik, J. Pirnos, J. Duras, H. Mocikova, M. Trneny,

. 2020 ; 99 (7) : 1583-1594. [pub] 20200606

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20024912

Grantová podpora
AZV16-31092A Ministerstvo Zdravotnictví Ceské Republiky
NV16-31092A MZ0 CEP - Centrální evidence projektů

Relapsing diffuse large B cell lymphomas (rDLBCL) represent a heterogeneous disease. This heterogeneity should be recognized and reflected, because it can deform the interpretation of clinical trial results. DLBCL patients with the first relapse and without CNS involvement were identified in the Czech Lymphoma Study Group (CLSG) database. Interval-to-therapy (ITT) was defined as the time between the first manifestation of rDLBCL and the start of any treatment. The overall survival (OS) of different ITT cohorts (< 7 vs. 7-21 vs. > 21 days) was compared. In total, 587 rDLBCLs (51.8% males) progressed with a median of 12.8 months (range 1.6 to 152.3) since the initial diagnosis (2000-2017). At the time of relapse, the median age was 67 years (range 22-95). First-line therapy was administered in 99.3% of the patients; CHOP and anti-CD20 were given to 69.2% and 84.7% of the patients, respectively. The salvage immune/chemotherapy was administered in 88.1% of the patients (39.2% platinum-based regimen). The median ITT was 20 days (range 1-851), but 23.2% of patients initiated therapy within 7 days. The 5-year OS was 17.4% (range 10-24.5%) vs. 20.5% (range 13.5-27.4%) vs. 42.2% (range 35.5-48.8%) for ITT < 7 vs. 7-21 vs. > 21 days (p < 0.001). ITT was associated with B symptoms (p 0.004), ECOG (p < 0.001), stage (p 0.002), bulky disease (p 0.005), elevated LDH (p < 0.001), and IPI (p < 0.001). The ITT mirrors the real clinical behavior of rDLBCL. There are patients (ITT < 7 days) with aggressive disease and a poor outcome. Conversely, there are rDLBCLs with ITT ≥ 21 days who survive for a long time.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20024912
003      
CZ-PrNML
005      
20250424111449.0
007      
ta
008      
201125s2020 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00277-020-04099-y $2 doi
035    __
$a (PubMed)32506244
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Janikova, Andrea $u Department of Internal Medicine - Hematology and Oncology, Masaryk University and University Hospital Brno, Jihlavska 20, 62500, Brno, Czech Republic. janikova.andrea@fnbrno.cz.
245    14
$a The interval between progression and therapy initiation is the key prognostic parameter in relapsing diffuse large B cell lymphoma: analysis from the Czech Lymphoma Study Group database (NIHIL) / $c A. Janikova, J. Michalka, Z. Bortlicek, R. Chloupkova, V. Campr, N. Kopalova, P. Klener, K. Benesova, J. Hamouzova, D. Belada, V. Prochazka, R. Pytlik, J. Pirnos, J. Duras, H. Mocikova, M. Trneny,
520    9_
$a Relapsing diffuse large B cell lymphomas (rDLBCL) represent a heterogeneous disease. This heterogeneity should be recognized and reflected, because it can deform the interpretation of clinical trial results. DLBCL patients with the first relapse and without CNS involvement were identified in the Czech Lymphoma Study Group (CLSG) database. Interval-to-therapy (ITT) was defined as the time between the first manifestation of rDLBCL and the start of any treatment. The overall survival (OS) of different ITT cohorts (< 7 vs. 7-21 vs. > 21 days) was compared. In total, 587 rDLBCLs (51.8% males) progressed with a median of 12.8 months (range 1.6 to 152.3) since the initial diagnosis (2000-2017). At the time of relapse, the median age was 67 years (range 22-95). First-line therapy was administered in 99.3% of the patients; CHOP and anti-CD20 were given to 69.2% and 84.7% of the patients, respectively. The salvage immune/chemotherapy was administered in 88.1% of the patients (39.2% platinum-based regimen). The median ITT was 20 days (range 1-851), but 23.2% of patients initiated therapy within 7 days. The 5-year OS was 17.4% (range 10-24.5%) vs. 20.5% (range 13.5-27.4%) vs. 42.2% (range 35.5-48.8%) for ITT < 7 vs. 7-21 vs. > 21 days (p < 0.001). ITT was associated with B symptoms (p 0.004), ECOG (p < 0.001), stage (p 0.002), bulky disease (p 0.005), elevated LDH (p < 0.001), and IPI (p < 0.001). The ITT mirrors the real clinical behavior of rDLBCL. There are patients (ITT < 7 days) with aggressive disease and a poor outcome. Conversely, there are rDLBCLs with ITT ≥ 21 days who survive for a long time.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a kohortové studie $7 D015331
650    _2
$a cyklofosfamid $x terapeutické užití $7 D003520
650    _2
$a databáze faktografické $7 D016208
650    _2
$a progrese nemoci $7 D018450
650    _2
$a doxorubicin $x terapeutické užití $7 D004317
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a difúzní velkobuněčný B-lymfom $x diagnóza $x epidemiologie $x patologie $x terapie $7 D016403
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a neoadjuvantní terapie $x metody $x statistika a číselné údaje $7 D020360
650    _2
$a prednison $x terapeutické užití $7 D011241
650    _2
$a prognóza $7 D011379
650    _2
$a recidiva $7 D012008
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a rituximab $x aplikace a dávkování $7 D000069283
650    12
$a čas zasáhnout při rozvinutí nemoci $x statistika a číselné údaje $7 D061665
650    _2
$a výsledek terapie $7 D016896
650    _2
$a vinkristin $x terapeutické užití $7 D014750
650    _2
$a mladý dospělý $7 D055815
651    _2
$a Česká republika $x epidemiologie $7 D018153
655    _2
$a časopisecké články $7 D016428
700    1_
$a Michalka, Jozef $u Department of Internal Medicine - Hematology and Oncology, Masaryk University and University Hospital Brno, Jihlavska 20, 62500, Brno, Czech Republic.
700    1_
$a Bortlicek, Zbynek $u Institute of Biostatistics and Analyses, Faculty of Medicine Masaryk University, Brno, Czech Republic.
700    1_
$a Chloupkova, Renata $u Institute of Biostatistics and Analyses, Faculty of Medicine Masaryk University, Brno, Czech Republic.
700    1_
$a Campr, Vit $u Department of Pathology and Molecular Medicine, 2nd Faculty of Medicine, Charles University and Faculty Hospital in Motol, Prague, Czech Republic.
700    1_
$a Kopálová, Nataša $u Department of Internal Medicine - Hematology and Oncology, Masaryk University and University Hospital Brno, Jihlavska 20, 62500, Brno, Czech Republic. $7 xx0331481
700    1_
$a Klener, Pavel $u 1st Department of Medicine, First Medical Faculty, Charles University and General University Hospital, Prague, Czech Republic.
700    1_
$a Benesova, Katerina $u 1st Department of Medicine, First Medical Faculty, Charles University and General University Hospital, Prague, Czech Republic.
700    1_
$a Hamouzova, Jitka $u 1st Department of Medicine, First Medical Faculty, Charles University and General University Hospital, Prague, Czech Republic.
700    1_
$a Belada, David $u 4th Department of Internal medicine - Hematology, University Hospital and Faculty of Medicine, Hradec Králové, Czech Republic.
700    1_
$a Prochazka, Vit $u Department of Hematology, University Hospital Olomouc, Olomouc, Czech Republic.
700    1_
$a Pytlik, Robert $u 1st Department of Medicine, First Medical Faculty, Charles University and General University Hospital, Prague, Czech Republic.
700    1_
$a Pirnos, Jan $u Department of Oncology, Hospital Ceske Budejovice, Ceske Budejovice, Czech Republic.
700    1_
$a Duras, Juraj $u Department of Clinical Hematology, Teaching Hospital Ostrava, Ostrava, Czech Republic.
700    1_
$a Mocikova, Heidi $u Internal Clinic of Hematology, University Hospital Kralovske Vinohrady and 3rd Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Trneny, Marek $u 1st Department of Medicine, First Medical Faculty, Charles University and General University Hospital, Prague, Czech Republic.
773    0_
$w MED00000424 $t Annals of hematology $x 1432-0584 $g Roč. 99, č. 7 (2020), s. 1583-1594
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32506244 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20250424111448 $b ABA008
999    __
$a ok $b bmc $g 1599057 $s 1115598
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 99 $c 7 $d 1583-1594 $e 20200606 $i 1432-0584 $m Annals of hematology $n Ann Hematol $x MED00000424
GRA    __
$a AZV16-31092A $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a NV16-31092A $p MZ0
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace